Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL701 and Pembrolizumab in Metastatic Pancreatic Ductal Adenocarcinoma
NCT05558982Phase 2Active, not recruiting
- Sponsor
- Georgetown University
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talabostat in pancreatic ductal adenocarcinoma (PDAC), sponsored by Georgetown University. Started Aug 2023; status: active, not recruiting.
02
Drugs
talabostat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05558982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05558982.